Cancer by Endeshaw, Meheret et al.
Trends in Liver Cancer Mortality in the United States: Dual 
Burden Among Foreign- and US-Born Persons
Meheret Endeshaw, MPH#1, Benjamin D. Hallowell, PhD#1, Hilda Razzaghi, PhD, MSPH1, 
Virginia Senkomago, PhD, MPH1, Matthew T. McKenna, MD, MPH2, Mona Saraiya, MD, 
MPH1
1Centers for Disease Control and Prevention, Atlanta, Georgia;
2Emory University School of Medicine, Atlanta, Georgia.
#
 These authors contributed equally to this work.
Abstract
BACKGROUND: Since the mid-1980s, the burden of liver cancer in the United States has 
doubled, with 31,411 new cases and 24,698 deaths occurring in 2014. Foreign-born individuals 
may be more likely to die of liver cancer than individuals in the general US-born population 
because of higher rates of hepatitis B infection, a low socioeconomic position, and language 
barriers that limit the receipt of early cancer detection and effective treatment.
METHODS: To determine whether liver cancer mortality rates were higher among foreign-born 
individuals versus US-born individuals in the United States, population-based cancer mortality 
data were obtained from the National Center for Health Statistics of the Centers for Disease 
Control and Prevention. Annual population estimates were obtained from the US Census Bureau’s 
American Community Survey. Age-adjusted mortality rates and rate ratios (RRs) for liver cancer 
stratified by birth place were calculated, and the average annual percent change (AAPC) was used 
to evaluate trends.
RESULTS: A total of 198,557 deaths from liver and intrahepatic bile duct cancer were recorded 
during 2005–2014, and 16% occurred among foreign-born individuals. Overall, foreign-born 
individuals had a 24% higher risk of liver cancer mortality than US-born individuals (RR, 1.24; 
95% confidence interval [CI], 1.22–1.25). Foreign-born individuals did not have any significant 
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changes in liver cancer mortality rates overall, but among US-born individuals, liver cancer 
mortality rates significantly increased (AAPC, 2.7; 95% CI, 2.1–3.3).
CONCLUSIONS: Efforts that address the major risk factors for liver cancer are needed to help to 
alleviate the health disparities observed among foreign-born individuals and reverse the increasing 
trend observed in the US-born population.
Keywords
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INTRODUCTION
Since the mid-1980s, the liver cancer mortality rate in the United States has doubled,1 with 
31,411 new cases and 24,698 deaths occurring in 2014.2 In the US population, liver cancer 
mortality rates are significantly increasing for nearly all sex, age, and race/ethnicity group 
stratifications.3,4 Globally, chronic infection with hepatitis B virus (HBV) or hepatitis C 
virus (HCV) is the major cause of liver cancer3,5; however, in the United States, obesity, 
chronic HCV infection, excessive alcohol consumption, and tobacco use are the leading 
causes of liver cancer.6
Foreign-born individuals represent a rapidly growing segment of the general US population, 
and from 1970 to 2010, the foreign-born population increased from 9.6 to 40.0 million 
individuals.7 This group is also more likely to develop and die of liver cancer than US-born 
individuals.8 According to their country of origin, HBV infection rates in the foreign-born 
population can range from 1 to 33 times the rates observed in the general US-born 
population, whereas their risk of HCV infection is lower than or similar to the risk for their 
US-born counterparts.9–12 Barriers such as limited English proficiency, an undocumented 
status, a mistrust or fear of an unfamiliar health care system, busy work schedules, and a low 
socioeconomic position all hinder foreign-born individuals from proper diagnosis and 
treatment, and this increases their risk of developing and dying of liver cancer.13,14 Although 
other studies have evaluated excess liver cancer mortality risk in the foreign-born 
population, the work is not contemporary8 or has been limited in geographic area or the 
race/ethnicity of the participants.15,16 We analyzed the most recent 10-year national 
mortality rate data (2005–2014) to provide current liver cancer mortality estimates by birth 
place, sex, and race/ethnicity and to determine the extent to which these rates are changing 
over time.
MATERIALS AND METHODS
Data Sources
Population-based cancer mortality data were obtained from the National Center for Health 
Statistics. The National Center for Health Statistics receives demographic and vital statistics 
from the National Vital Statistics System. The National Vital Statistics System collects 
information on sex, race, ethnicity, birth place, age at death, state of residence, and cause of 
death from death certificates filed in each state. Individuals whose death certificates stated 
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that they were born in 1 of the 50 states, the District of Columbia, or the US territories were 
categorized as US-born. Remaining cases with a recorded place of birth were categorized as 
foreign-born.17 Mortality data were selected with code C22 from the International 
Classification of Diseases, Tenth Revision, to identify all liver and intrahepatic bile duct 
cancers (called liver cancer in this article). A total of 200,925 deaths from liver cancer were 
recorded between 2005 and 2014. Cases with no recorded place of birth (1.2%) were 
excluded from all analyses.
Annual population estimates were obtained from the US Census Bureau’s American 
Community Survey (ACS). The ACS is a continuous national survey of randomly selected 
households and collects detailed information on the US population, including information on 
birth place.18 Information is collected regardless of residency status, so legal and 
undocumented individuals are surveyed and represented in the estimates.19 Because of this, 
the ACS is often used as a detailed source of information for the immigrant population in the 
United States.17 The ACS also provides 5-, 3-, and 1-year estimates of the US population 
and provides public-use microdata sample files that can be used to estimate the US 
population with social, housing, and demographic characteristics. We obtained the annual 
ACS public-use microdata sample files from 2005 to 2014 and estimated the US-born and 
foreign-born populations for age, race/ethnicity, and sex subgroups with the provided person 
weights.
Statistical Analysis
Mortality data from the National Center for Health Statistics and population estimates from 
the ACS for 2005–2014 were formatted with software from the Surveillance, Epidemiology, 
and End Results (SEER) program (SEER*Prep, version 2.5.3) to create a SEER*Stat 
database. Performing age adjustments to the 2000 US standard population, we calculated 
age-adjusted mortality rates for liver cancer among US- and foreign-born individuals. Rate 
ratios (RRs), standard errors, and 95% confidence intervals (CIs) were calculated with 
SEER*Stat (version 8.3.4).
The National Cancer Institute’s Joinpoint trend analysis software (version 4.5.0.1) was used 
to evaluate the annual percent change (APC) and average annual percent change (AAPC) in 
mortality rates from 2005 to 2014 by birth place (US- vs foreign-born) after stratification by 
sex, age, and race/ethnicity. APCs were calculated with a maximum of 1 joinpoint. The 
Monte Carlo permutation method was used to test whether the APC or AAPC was 
significantly different from 0.
RESULTS
Comparing Liver Cancer Mortality Rates: Foreign-Born Versus US-Born
From 2005 to 2014, 31,097 deaths from liver cancer were recorded for the foreign-born 
population, whereas 167,460 deaths were recorded among the US-born. Differences in liver 
cancer mortality rates by birth place, sex, race/ethnicity, and age groups are displayed in 
Table 1. Overall, foreign-born individuals had a higher risk of liver cancer mortality than 
US-born individuals (RR, 1.24; 95% CI, 1.22–1.25). This pattern remained after 
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stratification by sex with an RR of 1.17 (95% CI, 1.15–1.19) for males and with an RR of 
1.44 (95% CI, 1.42–1.48) for females. With stratification by sex and race/ethnicity, foreign-
born males who were non-Hispanic Asian/Pacific Islander (API; RR, 1.71; 95% CI, 1.59–
1.84) had higher mortality rates than US-born non-Hispanic APIs. In contrast, foreign-born 
men who were non-Hispanic black (RR, 0.61; 95% CI, 0.57–0.66) or Hispanic (RR, 0.52; 
95% CI, 0.51–0.54) had a significantly lower risk of death than US-born individuals of the 
same race/ethnicity. Non-Hispanic white and non-Hispanic API foreign-born women had 
higher liver cancer mortality rates than their US-born counterparts (RR for non-Hispanic 
whites, 1.16; 95% CI, 1.11–1.20; RR for non-Hispanic APIs, 1.56; 95% CI, 1.41–1.73). 
Foreign-born women who were non-Hispanic black (RR, 0.91; 95% CI, 0.83–0.99) or 
Hispanic (RR, 0.92; 95% CI, 0.88–0.96) had a significantly lower risk of death than their 
US-born counterparts. Foreign-born men and women had significantly higher mortality rates 
in most age groups examined than US-born men and women with the exception of men 50 to 
64 years old.
Trends in Liver Cancer Mortality Rates
Overall, liver cancer mortality rates significantly increased in the United States from 2005 to 
2014 (AAPC, 2.2; 95% CI, 1.0–3.4; Table 2). In general, rates significantly increased among 
men and women, among individuals 50 years old or older, and among non-Hispanic whites, 
non-Hispanic blacks, and Hispanics. Notably, the largest increases overall were observed 
among men and women aged 50 to 64 years, with identical increases in men (AAPC, 3.9; 
95% CI, 2.9–4.8) and women (AAPC, 3.9; 95% CI, 2.6–5.3).
Among foreign-born individuals overall, no significant changes were observed in liver 
cancer mortality rates from 2005 to 2014 (AAPC, 0.5; 95% CI, −1.5 to 2.6; Table 2). When 
they were stratified by sex, a significant increase in mortality rates was observed among men 
overall (AAPC, 1.2), with rates specifically increasing among men aged 50 to 64 years 
(AAPC, 1.5) and men aged ≥80 years (AAPC, 2.5) and among men of non-Hispanic white 
race/ethnicity (AAPC, 2.1). Among foreign-born women, no significant increases in 
mortality rates were observed overall, by age, or by race/ethnicity stratifications.
Liver cancer mortality rates significantly increased from 2005 to 2014 among US-born 
individuals (AAPC, 2.7; 95% CI, 2.1–3.3; Table 2). Among US-born men, liver cancer 
mortality rates significantly increased overall (AAPC, 2.7), with rates specifically increasing 
among men 50 years old or older and among non-Hispanic white, non-Hispanic black, and 
Hispanic men (Fig. 1). The trends for US-born women varied; significant increases were 
observed overall (AAPC, 2.1), among women 50 to 79 years old (AAPC for 50–64 years, 
4.5; AAPC for 65–79 years, 2.1), and among non-Hispanic white women (AAPC, 2.0) and 
non-Hispanic black women (AAPC, 2.3; Fig. 2 and Table 2).
DISCUSSION
Foreign-born individuals in the United States have an elevated risk of liver cancer mortality 
in comparison with the US-born population; however, their risk varies by age, sex, and race/
ethnicity. In both foreign- and US-born populations, liver cancer mortality rates were higher 
for men than women and for older individuals than younger age groups. The findings from 
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this study are consistent with other studies that have found higher liver cancer mortality rates 
among foreign-born individuals,8 men,3 and older age groups3,4,20,21 in comparison with 
their respective counterparts. When we analyzed trends over time, we found that the foreign-
born population had few significant changes in liver cancer mortality rates, whereas a 
significant increasing trend was observed in the US-born population for most race/
ethnicities, age groups, and sex stratifications.
Although foreign-born individuals generally had an elevated risk of liver cancer mortality, 
when they were stratified by ethnicity and sex, foreign-born non-Hispanic APIs were the 
only foreign-born group to have significantly higher liver cancer mortality for both sexes in 
comparison with their US-born counterparts. The high risk of liver cancer mortality 
observed among foreign-born APIs is likely to be partially explained by an elevated risk of 
acquiring an HBV infection before their immigration to the United States.22 HBV infection 
rates among foreign-born individuals can range from 1 to 33 times the observed rates among 
the general US-born population according to their country of origin and subsequent HBV 
vaccination rates.9,10 As childhood HBV vaccination rates continue to improve globally, it is 
likely that the liver cancer mortality rates among foreign-born individuals in the United 
States will decline.3 In contrast to foreign-born APIs, foreign-born Hispanic and non-
Hispanic black men had significantly lower rates of liver cancer mortality than their US-born 
counterparts. This may partly be explained by the higher rates of metabolic disorders, 
alcoholic liver disease, and HCV infection among US-born Hispanic men in comparison 
with their foreign-born counterparts,22 and it is likely that a similar trend is occurring among 
US-born non-Hispanic blacks.8 In contrast to previous work, this study did not find a 
significant decrease in liver cancer mortality rates among US- or foreign-born APIs.3,4 
Although this finding could be due to fluctuating mortality rates, these rates should be 
monitored and elucidated to improve interventions in this population.
Notably, our study also shows a continuation of the rapidly rising trend in liver cancer 
mortality rates in the US-born population. In the current study, liver cancer mortality rates 
significantly increased for nearly all sex, age, and race/ethnicity groups in the US-born 
population, and this aligned with previous findings.3,4 It is likely that this increase will 
continue, and it has been estimated that by 2030, liver cancer will the third leading cause of 
cancer mortality among men and women.23 Because of the limited treatment options 
available after diagnosis, the 5-year relative survival rate of patients with liver cancer is only 
14.8%.24 To alleviate the higher liver cancer mortality burden observed among foreign-born 
individuals and reverse the increasing trend observed in the US-born population, a 
combination of behavioral change programs for weight management, smoking cessation, 
reductions in alcohol consumption, and risk reduction for people who inject drugs as well as 
screening and treatment efforts for HBV and HCV will be needed.
Chronic infection with HBV or HCV is a well- documented risk factor for the development 
of liver cancer; currently in the United States, upward of 2.2 million individuals have 
chronic HBV,10,25 and 3.5 million have an HCV infection.26 HBV vaccination is 80% to 
100% effective in preventing disease. For patients with chronic HBV, early diagnosis and 
treatment can reduce the risk of liver cancer by 50% to 80%.27,28 There are curative 
treatment options for HCV infection that can reduce the risk of liver cancer by 75%.29,30 
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Improved hepatitis screening, HBV vaccination, and hepatitis treatment services for at-risk 
groups would help to alleviate the growing burden of liver cancer in the United States. The 
Centers for Disease Control and Prevention and the US Preventive Services Task Force both 
currently recommend HBV and HCV testing for individuals at high risk for infection. For 
HBV infection, foreign-born individuals whose country of origin has an HBV infection 
prevalence higher than 2% are considered a high-risk group.31 For HCV, the following 
factors are associated with a high risk of infection: current or past injection drug use, long-
term hemodialysis, a blood transfusion before 1992, high-risk sexual behaviors, and birth 
between 1945 and 1965.
Globally, chronic HBV and HCV infections account for a majority of liver cancer cases, but 
in the United States, the risk factors for liver cancer have been gradually changing.3,10 
Historically in the United States, HBV or HCV infections were the leading cause of liver 
cancer mortality. However, with the implementation of the childhood HBV vaccine and with 
the elimination of HCV from the nation’s blood supply, the prevalence of these infections in 
the United States has declined, whereas the incidence and mortality rate of liver cancer 
continue to increase.6 In a recent study, Makarova-Rusher et al6 calculated the population 
attributable fraction (PAF) for each of the major risk factors for liver cancer and showed how 
each risk factor contributed to the overall liver cancer burden in the United States. Their 
work found that metabolic disorders, including obesity, were responsible for 32% of the liver 
cancer burden in the United States, and they were followed by HCV (PAF, 20.5%), alcohol 
(PAF, 13.4%), smoking (PAF, 9%), HBV (PAF, 4.3%), and genetic disorders (PAF, 1.5%); 
these findings were consistent with another study.32 These results highlight that despite the 
low liver cancer risk conferred by some risk factors (eg, metabolic disorders or smoking), 
because of the high prevalence of these conditions in the population, they can account for a 
substantial number of cancer cases.
The main strength of this study is that it combines validated data from multiple sources to 
provide the most up-to-date comprehensive examination of liver cancer mortality rates by 
place of birth for the entire US population over the past decade. In addition, because the 
place of birth is frequently missing from cancer incidence data, this analysis approach 
provides the only way to accurately estimate the burden of cancer in the immigrant 
population at a national level, with only 1.2% of cases missing data for the place of birth. 
One limitation of this study is that mortality data were based on information obtained from 
death certificates, and this may have resulted in the undercounting of liver cancer deaths if 
the causes of death were not fully recorded. In addition, cancers frequently metastasize and 
spread to the liver, and this leaves the possibility that metastasized cancers from other sites 
could have been recorded as primary liver cancer. These issues were likely eliminated with 
the trend analysis because these issues are likely to occur at a constant rate over time.33 In 
addition, we did not have access to all variables relevant to liver cancer mortality 
(specifically, socioeconomic attributes, etiologic risk factors, and health insurance status). 
Finally, we did not differentiate between hepatocellular carcinoma and intrahepatic bile duct 
cancer in this article because of concerns about misclassification.34,35
In summary, foreign-born individuals in the United States have an elevated risk of liver 
cancer mortality in comparison with the US-born population. However, although the liver 
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cancer mortality rates among foreign-born individuals have remained fairly stable from 2005 
to 2014, the mortality rates among US-born individuals have significantly increased for 
nearly all race and sex subgroups. Efforts to address the major risk factors for liver cancer 
are needed to address the health disparities observed among foreign-born individuals and 
reverse the increasing trend observed in the US-born population.
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Figure 1. 
APCs in liver cancer mortality rates among men by nativity status: United States, 2005–
2014. APC indicates annual percent change; API, Asian/Pacific Islander.
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Figure 2. 
APCS in liver cancer mortality rates among women by nativity status: United States, 2005–
2014. APC indicates annual percent change; API, Asian/Pacific Islander.
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